Top Page
Novacyt
(OTC:ALNOV)
Novacyt (ALNOV) vs. iShares MSCI France ETF (EWQ)
Novacyt Business Overview & Revenue Model
Novacyt Earnings Call Summary
Novacyt Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.13M | 19.63M | 11.58M | 21.04M | 95.78M | 277.20M |
| Gross Profit | 979.86K | 32.07M | 3.73M | 5.75M | 29.68M | 211.13M |
| EBITDA | -6.52M | -34.31M | -18.24M | -11.68M | -4.20M | 174.97M |
| Net Income | -29.43M | -41.76M | -28.29M | -22.20M | -9.73M | 132.42M |
Balance Sheet | ||||||
| Total Assets | 133.81M | 70.63M | 133.81M | 140.90M | 183.70M | 234.28M |
| Cash, Cash Equivalents and Short-Term Investments | 44.06M | 30.46M | 44.06M | 86.98M | 101.75M | 91.77M |
| Total Debt | 13.70M | 11.88M | 13.70M | 872.00K | 1.87M | 2.38M |
| Total Liabilities | 46.57M | 22.75M | 46.57M | 25.68M | 41.88M | 83.57M |
| Stockholders Equity | 87.24M | 47.88M | 87.24M | 115.22M | 141.81M | 150.71M |
Cash Flow | ||||||
| Free Cash Flow | -15.67M | -11.01M | -25.66M | -14.14M | 11.59M | 101.80M |
| Operating Cash Flow | -15.34M | -9.15M | -24.99M | -13.73M | 15.69M | 102.98M |
| Investing Cash Flow | -6.46M | -1.88M | -13.94M | -577.00K | -5.03M | -7.96M |
| Financing Cash Flow | -2.25M | -1.84M | -3.97M | -516.00K | -599.00K | -5.04M |
Novacyt Technical Analysis
Novacyt Peers Comparison
Novacyt Corporate Events
Novacyt S.A. has announced a strategy update and an investor presentation detailing its growth plan and financial outlook for FY25. The company anticipates a slight increase in revenues for the second half of 2025, driven by new instrument sales, and expects improvements in EBITDA loss and cash outflow. Novacyt has set organic financial goals, including double-digit revenue growth starting FY26, maintaining a gross margin over 60%, and achieving EBITDA profitability. The company is focusing on restructuring and leveraging its core capabilities to meet emerging market needs, with investments to accelerate product launches and a mixed strategy of licensing and in-house product development.
Novacyt announced its monthly update on the Liquidity Agreement with Invest Securities SA, detailing the trading of ordinary shares from September 1 to September 30, 2025. During this period, 16,600 shares were purchased and 18,216 shares were sold, with the total number of shares held in treasury at 104,912. The total voting rights stand at 70,626,248 shares, which shareholders can use to determine their interest in the company. The Liquidity Agreement, governed by French law, allows Invest Securities to purchase shares on behalf of Novacyt, with shareholder approval granted for purchases up to €5.00 per share.
Novacyt S.A. is an international molecular diagnostics company specializing in genomic medicine, offering a wide range of molecular assays and instrumentation for sectors such as human health, animal health, and environmental applications. In its latest half-year financial report for 2025, Novacyt reported a slight decline in revenue to £9.8 million compared to the previous year, with a notable increase in demand for its reproductive health products, particularly in the Asia-Pacific region. The company also launched a new genomic research instrument, LightBench® Discover, and received EU accreditation for its Yourgene assays. Despite a reduced EBITDA loss of £4.1 million, Novacyt remains debt-free with a cash reserve of £23.7 million, reflecting its strategic focus on cost-saving measures and R&D investment. Looking ahead, Novacyt’s management is optimistic about achieving EBITDA profitability through organic growth, having resolved legacy issues and streamlined operations to focus on product development and market expansion.
Novacyt S.A. reported its unaudited interim results for the first half of 2025, highlighting a period of consolidation aimed at long-term growth. The company experienced a slight increase in underlying group revenue, driven by strong demand in its reproductive health products, particularly in the APAC region. Despite a reduction in statutory revenue, the company managed to reduce its EBITDA loss through cost-saving initiatives. Novacyt launched the LightBench® Discover instrument for genomic research labs, which has shown promising initial sales. The company also received EU accreditation for its Yourgene QST*R Base assay, demonstrating its commitment to maintaining high-quality standards in its products. With a robust balance sheet, Novacyt is well-positioned to continue investing in R&D and expanding its product adoption globally.
Novacyt S.A. reported its unaudited interim results for the first half of 2025, showing a period of consolidation aimed at long-term growth. The company achieved a 2% revenue increase, excluding the impact of a divestment, and saw strong demand in the reproductive health segment, particularly in the APAC region. The company launched the LightBench® Discover instrument for genomic research labs and received EU accreditation for key assays. Despite a slight decline in overall revenue, Novacyt reduced its EBITDA loss and maintained a strong cash position, positioning itself for future profitability and growth.
Novacyt S.A. announced it will release its unaudited interim results for the first half of 2025 on September 30, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.
Novacyt S.A. has announced the appointment of Singer Capital Markets as its joint corporate broker, effective immediately. This strategic move is expected to enhance Novacyt’s market presence and strengthen its financial advisory team, working alongside SP Angel, the company’s existing joint corporate broker. The appointment reflects Novacyt’s commitment to bolstering its corporate governance and investor relations, potentially impacting its operations and industry positioning positively.
Novacyt S.A. announced the conclusion of legal proceedings involving its non-trading subsidiary, Lab 21 Healthcare Ltd, which faced health and safety charges related to the use of biological agents at its Axminster site. Lab 21 pleaded guilty and was fined £52,000, a sum that will not materially affect Novacyt’s financial position. This resolution marks the end of the case, with no further legal action anticipated, thus allowing Novacyt to continue focusing on its core business operations without additional liabilities from this matter.
Novacyt S.A. has provided an update on its liquidity agreement with Invest Securities SA, detailing the trading of its ordinary shares during August 2025. The company reported that 26,541 shares were purchased and 30,020 shares were sold under the agreement. The total number of ordinary shares in the company is 70,626,248, which shareholders can use for calculations regarding their interests. The liquidity agreement, governed by French law, allows Invest Securities to purchase shares on behalf of Novacyt, with shareholder approval for purchases up to a maximum price of €5.00 per share.
Novacyt S.A. has provided an update on its liquidity agreement with Invest Securities SA, detailing the purchase and sale of ordinary shares during July 2025. The company reported that 14,521 shares were purchased and 8,516 shares were sold under the agreement. The total number of ordinary shares in the company is 70,626,248, which shareholders can use for interest calculations. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with its stakeholders.
Novacyt S.A. reported an unaudited trading update for the first half of 2025, with group revenue expected to be around £9.8 million, a slight decrease from the previous year. Despite this, the company saw growth in its clinical segment and NIPT technologies, with significant demand in the APAC region. Novacyt remains debt-free with a strong cash position, supporting its path to EBITDA profitability. The launch of LightBench® Discover positions Novacyt at the forefront of genomic research, marking a significant milestone post-restructuring.